Birdwatch Note
2024-01-30 06:24:15 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
mRNAワクチンは有効性が高く、重篤な有害事象も必ずしも多いわけではない 理論だけでなく、臨床上も優れたワクチンです https://www2.hosp.med.tottori-u.ac.jp/kanijiru/backnumber/vol8/special/31186.html 接種実績からもmRNAワクチンは極めて安全なワクチンだと確認されています https://mainichi.jp/articles/20231028/k00/00m/100/198000c また 「mRNA工場は日本にのみ乱立している」との主張は事実誤認です 上海・オックスフォード・ルワンダ・ケニヤ・豪州メルボルン等で、mRNAワクチン工場の建設や計画が進められています https://jp.reuters.com/markets/global-markets/KPRPX34JT5MSNMGJOMM3HROLKI-2023-11-28/ https://www.europeanpharmaceuticalreview.com/news/181939/modernas-mrna-vaccine-manufacturing-centre-begins-construction/ https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-aims-start-mrna-vaccine-output-rwanda-2025-2023-12-18/ https://prtimes.jp/main/html/rd/p/000000097.000064549.html https://www.industry.gov.au/news/mrna-vaccine-manufacturing-facility-commences-construction-melbourne AGCグループはドイツで製造受託サービスを提供しています https://www.agc.com/news/detail/1202417_2148.html
Written by CE7343FC743D4E7C1FAEA56CA165CB7D7D215C5D4998CE1CFF815B7E5688F59D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1751962244970365134
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1752216133590233103
- noteId - 1752216133590233103
- participantId -
- noteAuthorParticipantId - CE7343FC743D4E7C1FAEA56CA165CB7D7D215C5D4998CE1CFF815B7E5688F59D Participant Details
- createdAtMillis - 1706595855506
- tweetId - 1751962244970365134
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- mRNAワクチンは有効性が高く、重篤な有害事象も必ずしも多いわけではない 理論だけでなく、臨床上も優れたワクチンです https://www2.hosp.med.tottori-u.ac.jp/kanijiru/backnumber/vol8/special/31186.html 接種実績からもmRNAワクチンは極めて安全なワクチンだと確認されています https://mainichi.jp/articles/20231028/k00/00m/100/198000c また 「mRNA工場は日本にのみ乱立している」との主張は事実誤認です 上海・オックスフォード・ルワンダ・ケニヤ・豪州メルボルン等で、mRNAワクチン工場の建設や計画が進められています https://jp.reuters.com/markets/global-markets/KPRPX34JT5MSNMGJOMM3HROLKI-2023-11-28/ https://www.europeanpharmaceuticalreview.com/news/181939/modernas-mrna-vaccine-manufacturing-centre-begins-construction/ https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-aims-start-mrna-vaccine-output-rwanda-2025-2023-12-18/ https://prtimes.jp/main/html/rd/p/000000097.000064549.html https://www.industry.gov.au/news/mrna-vaccine-manufacturing-facility-commences-construction-melbourne AGCグループはドイツで製造受託サービスを提供しています https://www.agc.com/news/detail/1202417_2148.html
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-01-30 06:24:15 UTC (1706595855506) |
2024-01-30 11:47:10 UTC (1706615230570) |
CURRENTLY_RATED_HELPFUL | 2024-01-31 02:06:08 UTC (1706666768602) |
CURRENTLY_RATED_HELPFUL | 2024-01-30 11:47:10 UTC (1706615230570) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-01-30 18:21:17 -0600 | Rating Details | |
| 2024-01-30 17:09:34 -0600 | Rating Details | |
| 2024-01-30 16:53:45 -0600 | Rating Details | |
| 2024-01-30 16:51:32 -0600 | Rating Details | |
| 2024-01-30 16:41:35 -0600 | Rating Details | |
| 2024-01-30 16:38:30 -0600 | Rating Details | |
| 2024-01-30 16:27:09 -0600 | Rating Details | |
| 2024-01-30 15:50:20 -0600 | Rating Details | |
| 2024-01-30 08:08:30 -0600 | Rating Details | |
| 2024-01-30 04:10:10 -0600 | Rating Details | |
| 2024-01-30 03:03:12 -0600 | Rating Details | |
| 2024-01-30 03:00:05 -0600 | Rating Details | |
| 2024-01-30 02:32:26 -0600 | Rating Details | |
| 2024-01-30 02:08:43 -0600 | Rating Details | |
| 2024-01-30 01:44:06 -0600 | Rating Details | |
| 2024-01-30 01:43:54 -0600 | Rating Details | |
| 2024-01-30 01:35:08 -0600 | Rating Details | |
| 2024-01-30 01:29:50 -0600 | Rating Details | |
| 2024-01-30 01:02:35 -0600 | Rating Details | |
| 2024-01-30 00:55:52 -0600 | Rating Details | |
| 2024-01-30 00:50:54 -0600 | Rating Details | |
| 2024-01-30 00:45:41 -0600 | Rating Details | |
| 2024-01-30 00:45:27 -0600 | Rating Details | |
| 2024-01-30 00:40:16 -0600 | Rating Details | |
| 2024-01-30 00:34:47 -0600 | Rating Details | |
| 2024-01-30 00:32:41 -0600 | Rating Details | |
| 2024-01-31 12:46:27 -0600 | Rating Details | |
| 2024-01-31 01:55:51 -0600 | Rating Details | |
| 2024-01-30 19:09:23 -0600 | Rating Details | |
| 2024-02-01 00:22:25 -0600 | Rating Details | |
| 2024-01-31 09:35:42 -0600 | Rating Details | |
| 2024-01-30 21:06:20 -0600 | Rating Details | |
| 2024-01-30 18:08:25 -0600 | Rating Details | |
| 2024-01-30 17:26:37 -0600 | Rating Details | |
| 2024-01-30 17:12:58 -0600 | Rating Details | |
| 2024-01-30 16:42:55 -0600 | Rating Details | |
| 2024-01-30 16:28:46 -0600 | Rating Details | |
| 2024-01-30 07:10:54 -0600 | Rating Details | |
| 2024-01-30 04:55:56 -0600 | Rating Details | |
| 2024-01-30 03:20:19 -0600 | Rating Details | |
| 2024-01-30 01:55:44 -0600 | Rating Details | |
| 2024-01-30 01:53:25 -0600 | Rating Details | |
| 2024-01-30 01:47:11 -0600 | Rating Details | |
| 2024-01-30 01:32:49 -0600 | Rating Details | |
| 2024-01-30 01:00:14 -0600 | Rating Details | |
| 2024-01-30 00:56:06 -0600 | Rating Details | |
| 2024-01-30 00:45:30 -0600 | Rating Details | |
| 2024-01-30 00:45:25 -0600 | Rating Details | |
| 2024-01-30 00:44:52 -0600 | Rating Details |